Abstract: A power source fault prediction and control system includes a plurality of power sources, such as generator sets connected in parallel, a controller, and a data acquisition and analysis module. The data acquisition and analysis module is configured to receive sensor data from a sensor, analyze the sensor data, predict a future fault scenario at a first time, and optionally send an instruction to the controller to change an operational parameter of a respective power source, such as the generator set. The instruction is configured to delay the fault scenario to a second time after the first time.

Abstract: A synergistic antimicrobial composition having two components. The first component is tetrakis(hydroxymethyl)phosphonium sulfate. The second component is glyoxal.

Abstract: The invention relates to at least one chemical entity chosen from compounds of formula (I): and pharmaceutically acceptable derivative(s) thereof. The invention also relates to processes for the preparation of compound(s) of formula (I), pharmaceutical compositions containing compound(s) of formula (I) and to the use of compound(s) of formula (I) in medicine, particularly in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.

Abstract: The invention relates to compounds of formula (I) processes for their preparation, pharmaceutical compositions containing them and to their use in medicine, particularly use in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.

Abstract: The invention relates to compounds of formula (I) processes for their preparation, pharmaceutical compositions containing them and to their use in medicine, particularly use in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.

Abstract: The invention relates to compounds of formula (I) processes for their preparation, pharmaceutical compositions containing them and to their use in medicine, particularly use in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.

Abstract: A vehicle locating unit with improved power management. A receiver receives a signal from a network of communication sources. A signal strength monitoring subsystem determines which of the communication sources are transmitting the strongest signals. A power management subsystem is responsive to the signal strength monitoring subsystem and is configured to alternatively enter sleep and wake-up modes, synchronize the wake-up mode to the communication source transmitting the strongest signal, and test the signal strength of at least one additional communication source according to a predefined sequence.

Abstract: A vehicle locating unit with a receiver for receiving a signal from a network of communication sources, a transponder activated when a communication source sends a message to the receiver, and a power supply regulating circuit for regulating a nominal input voltage and powering the receiver and the transponder. A protection circuit is responsive to an injected input voltage and configured to clamp the injected (high level) input voltage at a predetermined maximum voltage.

Abstract: A vehicle locating unit features a receiver which receives a signal from a network of communication sources and a transponder activated when a communication source sends a message to the receiver. There is a transmitter for sending signals to the communication sources and a proof of life subsystem configured to periodically send a proof of life message via the transmitter to the communication sources.

Abstract: The invention relates to compounds of formula (I): wherein substituents are as defined.

Abstract: The invention relates to compounds of formula (I): wherein substituents are as defined.

Abstract: The invention relates to novel chemical compounds, pharmaceutically acceptable derivatives thereof, processes for their preparation, pharmaceutical compositions containing them, and to their use in medicine, particularly use in the amelioration of a clinical condition for which a thrombin inhibitor is indicated.

Abstract: The invention relates to compounds of formula (Ic) processes for their preparation, pharmaceutical compositions containing them and to their use in medicine, particularly use in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.

Abstract: The invention relates to compounds of formula (Ic) processes for their preparation, pharmaceutical compositions containing them and to their use in medicine, particularly use in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.

Abstract: The invention relates to compounds of formula (I): wherein substituents are as defined.

Abstract: The present invention includes (E)-2-(5-Chlorothien-2-yl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl)ethenesulfonamide in substantially crystalline form, pharmaceutical formulations thereof, processes for preparing it, and its use in medicine, particularly use in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.

Abstract: The invention relates to compounds of formula (I) processes for their preparation, pharmaceutical compositions containing them and to their use in medicine, particularly use in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.

Abstract: A shielding device (102) is provided for a circuit board that has components thereon which operate at 10 GHz or above. The shielding device (102) has a face with a plurality of component recesses (104-109) therein each for receiving a portion of at least one component. At least some of the shielding device (102) is formed of a material that is absorptive of electromagnetic radiation having a frequency of about 10 GHz or above. The electrical properties of the material and the dimensions of the component recesses (104-109) are arranged such that, when the shielding device (102) is used in conjunction with a circuit board, the shielding device (102) suppresses undesired propagation of electromagnetic radiation between components of the circuit board.

Abstract: The present invention relates to novel compounds and pharmaceutically acceptable derivatives thereof. The invention also relates to processes for the preparation of the compounds, pharmaceutical compositions containing the compounds, and to the use of compounds in medicine, particularly in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.

Abstract: The invention relates to compounds of formula (I) pharmaceutical compositions containing the same as well as methods of treating patients suffering from a condition susceptible to amelioration by a Factor Xa inhibitor using the same.